Cita APA

Troya, J., Ryan, P., Ribera, E., Podzamczer Palter, D., Hontanon, V., Terrón, J. A., . . . Group, G. S. (2016). Abacavir/Lamivudine plus Rilpivirine Is an Effective and Safe Strategy for HIV-1 Suppressed Patients: 48 Week Results of the SIMRIKI Retrospective Study.

Citación estilo Chicago

Troya, Jesús, et al. Abacavir/Lamivudine Plus Rilpivirine Is an Effective and Safe Strategy for HIV-1 Suppressed Patients: 48 Week Results of the SIMRIKI Retrospective Study. 2016.

Cita MLA

Troya, Jesús, et al. Abacavir/Lamivudine Plus Rilpivirine Is an Effective and Safe Strategy for HIV-1 Suppressed Patients: 48 Week Results of the SIMRIKI Retrospective Study. 2016.